Intelligence Profile
Clinical Applications
Retatrutide is a novel triple receptor agonist being investigated for multiple metabolic conditions, with clinical evidence emerging from ongoing Phase 3 trials and systematic reviews.
Type 2 Diabetes
Retatrutide is being evaluated for glycemic control in adults with type 2 diabetes. The completed Phase 3 TRANSCEND-T2D-1 trial (NCT06354660) studied its effects compared to placebo in participants with inadequate glycemic control despite diet and exercise. Early reports suggest the compound demonstrates blood sugar lowering effects, though detailed trial results are not yet available in the provided evidence.
A Phase 1 study is currently recruiting participants to evaluate retatrutide's effects on insulin secretion and insulin sensitivity in adults with type 2 diabetes mellitus (NCT06982859).
Obesity and Weight Management
Clinical trials are investigating retatrutide for obesity treatment, including a Phase 3 study in participants with obesity and cardiovascular disease (NCT05882045). Systematic reviews examining drugs for adults with overweight or obesity have included retatrutide in comparative analyses, though specific efficacy data from these reviews is not detailed in the available evidence.
The compound appears to promote weight loss based on trial reports, positioning it among the newer incretin-based therapies being studied for obesity management.
Cardiovascular and Metabolic Parameters
A systematic review and meta-analysis of randomized controlled trials examined retatrutide's effects on blood pressure and lipid levels, suggesting potential cardiovascular benefits beyond glucose control and weight loss. However, specific findings from this analysis are not detailed in the current evidence.
Safety Considerations
The clinical development program includes safety assessments, with studies examining retatrutide in participants with impaired renal function (NCT05611957) and drug interaction studies with commonly prescribed medications like metoprolol (NCT06808802).
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult healthcare providers for personalized treatment recommendations.
Note: Detailed efficacy and safety data from the completed Phase 3 trials are not fully available in the provided evidence. Clinical applications are based on ongoing trial descriptions and limited published reports.